Effects of roxadustat versus recombination human erythropoietin on coronary artery calcification in maintenance hemodialysis patients
- VernacularTitle:对比罗沙司他与重组人促红细胞生成素对维持性血液透析患者冠状动脉钙化的影响
- Author:
Yang WEN
1
;
Yunfeng XIA
1
;
Hua GAN
1
;
Zhengrong LI
1
;
Ying GONG
1
Author Information
1. Dept. of Nephrology，the First Affiliated Hospital of Chongqing Medical University，Chongqing 400016，China
- Publication Type:Journal Article
- Keywords:
roxadustat;
recombination human erythropoietin;
maintenance hemodialysis;
coronary artery calcification
- From:
China Pharmacy
2024;35(5):590-594
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the effects of roxadustat and recombination human erythropoietin （rHuEPO） on coronary artery calcification in maintenance hemodialysis （MHD） patients. METHODS In retrospective analysis， MHD patients prescribed roxadustat in the Blood Purification Center of the First Affiliated Hospital of Chongqing Medical University from April 2019 to June 2021 were selected as the ROX group （56 patients）， and MHD patients prescribed rHuEPO during the same period were selected as the EPO group （60 patients）， and follow-up observation was conducted for 12 months. The differences in laboratory index， coronary artery calcification score （CACS）， and cardiac ultrasound parameters before and after treatment as well as the occurrence of cardiac and cerebrovascular adverse events during follow-up period were compared between the two groups. RESULTS There was no statistical difference in CACS between the two groups before and after treatment （P＞0.05）； but the difference of CACS in the ROX group was significantly lower than the EPO group （P＜0.05）. There was no statistically significant difference in cardiac ultrasound parameters and laboratory indexes between the two groups before and after treatment （P＜0.05）. The incidence of apoplexy and myocardial infarction in the ROX group was lower than that in the EPO group （P＜0.05）， and there was no statistically significant difference in the incidence of hospitalization due to heart failure between the two groups （P＞0.05）. CONCLUSIONS Compared with rHuEPO， roxadustat may have a positive effect on delaying coronary artery calcification in MHD patients and may be beneficial in reducing the incidence of myocardial infarction and apoplexy in MHD patients.
